O uso dos compostos da cannabis para farmacoterapia da doença de Gilles de la Tourette

Sara Antonini; Matheus Henrique Rocha Aguiar; Emilene Dias Fiuza Ferreira

doi:10.4025/arqmudi.v30i1.77730

Autores

Sara Antonini Universidade Cesumar. Maringá, PR, Brasil. Autor https://orcid.org/0009-0009-4966-8160
Matheus Henrique Rocha Aguiar Universidade Cesumar. Maringá, PR, Brasil. Autor https://orcid.org/0009-0007-4736-4804
Emilene Dias Fiuza Ferreira Universidade Cesumar. Maringá, PR, Brasil. Autor https://orcid.org/0000-0002-6235-6462

DOI:

https://doi.org/10.4025/arqmudi.v30i1.77730

Palavras-chave:

Cannabis sativa, Síndrome de Tourette, Tratamento, Maconha Medicinal

Resumo

Objetivo: analisar a relação medicinal da Cannabis com a Síndrome de Tourette. Métodos: a presente revisão integrativa de literatura usou-se das bases de dados PubMed, LILACS, MedLine, SciELO e Science Direct para filtrar os artigos publicados nos últimos 5 anos disponíveis integralmente nos bancos de dados em inglês, português ou espanhol cujo enfoque é a utilização desses compostos para o distúrbio. Resultados: a eficácia do tratamento varia de acordo com a dosagem e a forma de administração, com efeitos adversos leves comuns, como sedação, boca seca e tontura, que destacam o desafio na padronização e homogeneidade dos tratamentos nas novas evidências. Conclusão: Apesar de promissores, os resultados ainda são inconclusivos e insuficientes para fundamentar uma recomendação clínica e mais estudos futuros com metodologias robustas e amostras maiores são necessários para confirmar a eficácia da Cannabis no tratamento desse transtorno.

Downloads

Os dados de download ainda não estão disponíveis.

Referências

1. Maiola R. Georges Gilles de la Tourette. Medicina (B Aires). 2022;82(3):459–60.
2. American Psychiatric Association. DSM-5: Manual diagnóstico e estatístico de transtornos mentais. Porto Alegre: Artmed; 2014.
3. Nieto-Pico AM, Rueda-Vargas A, Mora-Bautista VM. Trastornos por tics en niÃ±os: un caso con retraso diagnóstico. Ces Med. 2019;33(2):126–33.
4. Fernández S, Larraguibel Q. Síndrome de Tourette: Tratamiento farmacológico en pacientes pediátricos, una puesta al día. Rev Chil Psiquiatr Neurol Infanc Adolesc. 2020;31(2):91–104.
5. Anis S, Davidov A, Benâ€Ari Y, Pellegrino G, Snir Y, Goldstein M, et al. Medical Cannabis for Gilles de la Tourette syndrome: An openâ€label prospective study. Behav Neurol. 2022;2022:5141773.
6. Dyke K, Naros G, Hidding U, Rogalewski A, Bäumer T, Dresel C, et al. Effects of single-session cathodal transcranial direct current stimulation on tic symptoms in Tourette's syndrome. Exp Brain Res. 2019;237(11):2853–63.
7. Singer HS, Augustine F. Controversies surrounding the pathophysiology of tics. J Child Neurol. 2019;34(13):851–62.
8. Roessner V, Hoekstra PJ, Rizzo R, Stern JS, Mathews CA, Porta M, et al. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022;31(3):403–20.
9. MÃ¼ller-Vahl KR, Roessner V, Rizzo R, Jakubovski E, Stern JS, Hoekstra PJ, et al. European clinical guidelines for Tourette syndrome and other tic disorders: summary statement. Eur Child Adolesc Psychiatry. 2022;31(3):377–82.
10. Groh CJ. Medical Cannabis and psychiatric disorders: Implications for psychiatric nurses. J Am Psychiatr Nurses Assoc. 2022;28(1):91–103.
11. Szejko N, Jakubovski E, MÃ¼ller-Vahl KR. Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. Neurol Neurochir Pol. 2022;56(1):28–38.
12. Brasil. Conselho Federal de Medicina. Resolução CFM nº 2.324, de 11 de outubro de 2022. Diário Oficial da União, Brasília, DF; 2022 Oct 14.
13. Efron D, Taylor K. Medicinal Cannabis for paediatric developmental, behavioural and mental health disorders. Int J Environ Res Public Health. 2023;20(8):5430.
14. Hoch E, Niemann D, von Keller R, Schneider M, Friemel CM, Preuss UW, et al. How effective and safe is medical Cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269:87–105.
15. Klumpers LE, Thacker DL. A brief background on Cannabis: From plant to medical indications. J AOAC Int. 2019;102(2):412–20.
16. Bloch MH, Panza KE, Landeros-Weisenberger A, Brennan BD, Leckman JF, Pittenger C. A phase-2 pilot study of a therapeutic combination of Î”9-tetrahydracannabinol and palmitoylethanolamide for adults with Tourette’s syndrome. J Neuropsychiatry Clin Neurosci. 2021;33(4):328–36.
17. MÃ¼ller-Vahl KR. Cannabinoids in the treatment of selected mental illnesses: Practical approach and overview of the literature. Pharmacopsychiatry. 2024;57(1):14–23.
18. Schwittay MA, Steinbrecher A, Lobsien E. Tic reduction in adult onset Gilles De La Tourette syndrome using as required Nabiximols spray. Tremor Other Hyperkinet Mov. 2021;11:30.
19. Aran A, Cayam-Rand D. Medical Cannabis in children. Rambam Maimonides Med J. 2020;11(1):e0002.
20. MÃ¼ller-Vahl KR, Pisarenko A, Jakubovski E, Fremer C, SchÃ¼rmann M, Kolbe H, et al. Endocannabinoid modulation using monoacylglycerol lipase inhibition in Tourette syndrome: a phase 1 randomized, placebo-controlled study. Pharmacopsychiatry. 2022;55(3):148–56.
21. MÃ¼ller-Vahl KR, Jakubovski E, SchÃ¼rmann M, Kolbe H, Davies P, Pisarenko A, et al. CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo-controlled, phase IIIb superiority study. Psychiatry Res. 2023;323:115135.
22. Serag I, ElSayed M, Abdelrahman S, Elbarbary M. Efficacy of Cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2024;80(10):1483–93.
23. MÃ¼ller-Vahl KR, Jakubovski E, Pisarenko A, Fremer C, Kolbe H, SchÃ¼rmann M, et al. Monoacylglycerol lipase inhibition in Tourette syndrome: a 12-week, randomized, controlled study. Mov Disord. 2021;36(10):2413–8.
24. Jakubovski E, Martino D, MÃ¼ller-Vahl KR. The CANNA-TICS study protocol: a randomized multi-center double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders. Front Psychiatry. 2020;11:575826.
25. Mosley PE, Herbert A, Malpas G, Dwyer J, Martin JH. Tetrahydrocannabinol and cannabidiol in Tourette syndrome. NEJM Evid. 2023;2(9):EVIDoa2300012.
26. Lasch F, Trottmann M, Goetz S, Jakubovski E, MÃ¼ller-Vahl KR. Potential impact of COVIDâ€19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNAâ€TICS study. Pharm Stat. 2021;20(3):675–91.
27. Szejko N, Roessner V, Rizzo R, Jakubovski E, Hoekstra PJ, MÃ¼ller-Vahl KR. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part I: assessment. Eur Child Adolesc Psychiatry. 2022;31(3):383–402.